Journal profile · Oncology
Cancer and Metastasis Reviews
ISSN 0167-7659 · eISSN 1573-7233 · Springer US · UNITED STATES · Quarterly · Founded 1982
Cancer and Metastasis Reviews: CAS Zone 2 · Medicine (2025 upgraded edition); impact factor 12.76; hybrid open access; APC about USD 3,790; median 120 days to acceptance (44 articles, last 24 months); community-reported acceptance: fairly hard; 71 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Cancer and Metastasis Reviews is published by Springer US and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Cancer Cells and Metastasis, Cancer, Hypoxia, and Metabolism and Cancer Genomics and Diagnostics, together about 26.3% of its articles. Its main subfields are Oncology. (generated from OpenAlex topic counts and CAS ranking data)
Aims and Scope Research advances over the past decades have in many cases transformed advanced cancer from a lethal diagnosis to a manageable chronic condition; in some cases, advanced cancers can even be cured. These advances have been driven by fundamental research into the mechanisms which malignant transformation subverts the machinery of the cancer cell and impacts the tumor microenvironment. Translational work guided by these basic discoveries has led to better strategies for cancer prevention, guided the creation of new targeted cancer therapies, and spurred the performance of clinical trials to assess efficacy of new therapeutic modalities. The volume of publications on these topics is vast, and increasing, and the need for thoughtful analysis and synopsis is greater than ever. The goal of Cancer & Metastasis Reviews is to highlight recent significant advances in basic, translational, and clinical research, emphasizing studies that have high impact for control of cancer, or have outstanding potential in this regard. Topics that will be considered include: Function of oncogenes and tumor suppressors Regulation of cell death in cancer Control of cell cycle and DNA repair in cancer Inflammation and immune system defects related to carcinogenesis Impact of the microbiome on carcinogenesis and therapeutic response Changes in cell metabolism linked to transformation Genetic and epigenetic changes during tumor formation, progression, metastasis, and response to treatment Tumor microenvironment, pre-metastatic and metastatic niches, and tumor dormancy Aging and cancer Development of molecularly targeted cancer therapies, including cellular therapies and immunotherapies, and clinical trials of such agents Biological and molecular factors related to cancer risk, cancer prevention, and cancer interception Systems biology and computational biology technologies for identification and characterization of cancer targets Technologies for early detection of new or recurrent tumors, and for monitoring response to treatment Predictive and prognostic biomarkers for cancer therapy. Cancer Disparities Founding Editors Isaiah J. Fidler†, PhD Garth L. Nicolson(Emeritus), PhD George Poste, PhD, Arizona State University, Scottsdale, Arizona, USA
From the journal's Aims & Scope
Research area (LetPub): Oncology
Editor-in-chief Erica GolemisPublisher website
Main research topics OpenAlex counts of recent articles; shares are approximate
- Cancer Cells and MetastasisMedicine10.7%
- Cancer, Hypoxia, and MetabolismBiochemistry, Genetics and Molecular Biology8.6%
- Cancer Genomics and DiagnosticsBiochemistry, Genetics and Molecular Biology7%
- Cell Adhesion Molecules ResearchMedicine5.2%
- Angiogenesis and VEGF in CancerBiochemistry, Genetics and Molecular Biology5.1%
- Cancer Immunotherapy and BiomarkersMedicine4.5%
- Immunotherapy and Immune ResponsesImmunology and Microbiology4.4%
- Peptidase Inhibition and AnalysisMedicine4.3%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Oncology | Zone 2 |
Top journal: noReview journal: yes
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Oncology | Zone 2 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Oncology | Zone 2 |
Top journal: noReview journal: yes
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
MEDLINEEmbaseCASPublisher website
Other: Google Scholar, EBSCO, ProQuest, Dimensions, CNKI, Baidu, Naver, OCLC, Portico, CLOCKSS
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 12.76LetPub ·
- Impact factor (publisher) 2025
- 12.7Publisher website ·
- 5-year impact factor (publisher) 2025
- 12.1Publisher website ·
- CiteScore 2026-06
- 16.3LetPub ·
- SJR 2026-06
- 3.22LetPub ·
- SNIP 2026-06
- 2.2LetPub ·
- h-index
- 134LetPub ·
- h-index
- 217OpenAlex ·
- i10-index
- 1,663OpenAlex ·
- 2-year mean citedness
- 12.24OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 52.11%LetPub ·
Volume
- Articles per year
- 73LetPub ·
- Downloads per year (publisher) 2025
- 962,800Publisher website ·
Articles by year OpenAlex count · 2,126 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 73 | 47 | 71 |
| 2025 | 71 | 44 | 881 |
| 2024 | 79 | 47 | 1,778 |
| 2023 | 85 | 62 | 2,773 |
| 2022 | 55 | 36 | 1,748 |
| 2021 | 74 | 56 | 3,327 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
120 daysMedian, submission to acceptance · P25–P75 93 days – 171 days
- Acceptance to online
- median 17 days (44 articles)
- Submission to online
- median 140 days
- Sample
- 44 articles with submission and acceptance dates (47 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 6–12 weeksLetPub ·
- Average acceptance (community reports)
- Fairly hardLetPub ·
- Submission to first decision
- 8 daysPublisher website ·
- Peer review
- Double anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 3,790 / EUR 2,890 / GBP 2,490 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare5 items from the author guidelines
- Abstract
- 150–250 words
- Keywords
- ≥ 4
- Manuscript length
- ≤ 8,000 words
- Reference style
- Numbered, in order of citation
- Suggested reviewers
- Optional
Article types accepted3, with length limits
- full reviewsFull reviews address topics of established importance or newly emerging fields, stressing recent developments. Full reviews should be 4,000-8,000 words (excludi…Length not stated
- mini-reviewsMini-reviews are similar to full review articles, but can be more speculative and forward-looking. These articles should be 3,000-4,000 words (excluding referen…Length not stated
- reviewds, stressing recent developments. Full reviews should be 4,000-8,000 words (excluding references and figure legends) with a minimum ofmain text ≤ 8,000 words
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Data availability, License & copyright, Open access
- AI use Generative AI Images
Please check Springer’s policy on generative AI images and make sure your work adheres to the principles described therein. Back to top
Source ↗Publisher website ·- Authorship Authorship principles
These guidelines describe authorship principles and good authorship practices to which prospective authors should adhere to. Authorship clarified The Journal and Publisher assume all authors agreed with the content and that all gave explicit consent to submit and that they obtained consent from the responsible authorities at the institute/organization where the work has been carried out, before th…
Source ↗Publisher website ·- Conflicts of interest Competing Interests
Authors are requested to disclose interests that are directly or indirectly related to the work submitted for publication. Interests within the last 3 years of beginning the work (conducting the research and preparing the work for submission) should be reported. Interests outside the 3-year time frame must be disclosed if they could reasonably be perceived as influencing the submitted work. Disclo…
Source ↗Publisher website ·- Data availability Data availability statements
All original research must include a data availability statement. This statement should explain how to access data supporting the results and analysis in the article, including links/citations to publicly archived datasets analysed or generated during the study. Please see our full policy here. If it is not possible to share research data publicly, for instance when individual privacy could be com…
Source ↗Publisher website ·- License & copyright Copyright
Permissions required for previously published material Model summary
Open Choice articles do not require transfer of copyright as the copyright remains with the author. In opting for open access, the author(s) agree to publish the article under a Creative Commons license. Details of the OA licences offered to authors can be found on the individual journal website, in the journal's How to publish with us guide. Back to top
Source ↗Publisher website ·- Open access Open access publishing
To find out more about publishing your work Open Access in Cancer and Metastasis Reviews, including information on fees, funding and licences, visit our Open access publishing page. Back to top
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Springer US
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Quarterly
- Founded
- 1982
- ISSN
- 0167-7659
- Electronic ISSN
- 1573-7233
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
- Author guidelines ↗LetPub
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Cancer and Metastasis Reviews
What CAS zone is Cancer and Metastasis Reviews in?
In the 2025 upgraded edition of the CAS Journal Ranking, Cancer and Metastasis Reviews is in Zone 2 of Medicine, and in Zone 2 of the minor category Oncology. In the 2026 Xinrui edition it is in Zone 1 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Cancer and Metastasis Reviews?
The latest impact factor listed by LetPub is 12.76; CiteScore 16.3, h-index 217.
How long does peer review take at Cancer and Metastasis Reviews?
Based on the dates recorded on 44 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 120 days (interquartile range 93–171 days); authors report an average review time of 6–12 weeks; the community-reported acceptance is “Fairly hard”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Cancer and Metastasis Reviews?
According to the journal's author guidelines: Abstract: 150–250 words; Keywords: ≥ 4; Manuscript length: ≤ 8,000 words; Reference style: Numbered, in order of citation; Suggested reviewers: Optional. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Which databases index Cancer and Metastasis Reviews?
According to LetPub and DOAJ records, Cancer and Metastasis Reviews is indexed in SCIE and Scopus. The journal's website also lists MEDLINE, Embase and CAS; that list has not been checked against each database.
Is Cancer and Metastasis Reviews open access, and what is the APC?
Cancer and Metastasis Reviews is a hybrid journal. For open-access publication: APC about USD 3,790.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .